Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Phase I Dose Cohort # 1 (100 mg Per Day)	3
Overall Study	STARTED	Phase I Dose Cohort # 2 (150 mg Per Day)	3
Overall Study	STARTED	Phase I Dose Cohort # 3 (200 mg Per Day)	10
Overall Study	STARTED	Phase II Participants	22
Overall Study	COMPLETED	Phase I Dose Cohort # 1 (100 mg Per Day)	3
Overall Study	COMPLETED	Phase I Dose Cohort # 2 (150 mg Per Day)	3
Overall Study	COMPLETED	Phase I Dose Cohort # 3 (200 mg Per Day)	6
Overall Study	COMPLETED	Phase II Participants	12
Overall Study	NOT COMPLETED	Phase I Dose Cohort # 1 (100 mg Per Day)	0
Overall Study	NOT COMPLETED	Phase I Dose Cohort # 2 (150 mg Per Day)	0
Overall Study	NOT COMPLETED	Phase I Dose Cohort # 3 (200 mg Per Day)	4
Overall Study	NOT COMPLETED	Phase II Participants	10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00550615/flow